|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effectiveness of an intervention for reducing social stigma towards mental illness in adolescents显示文摘AIM: To evaluate the effectiveness of an intervention for reducing social stigma towards mental illness in adolescents. The effect of gender and knowledge of someone with mental illness was measured. METHODS: Two hundred and eighty secondary school students were evaluated using the Community Attitudes towards Mental Illness(CAMI) questionnaire. The schools were randomized and some received the intervention and others acted as the control group. The programme consisted of providing information via a documentary film and of contact with healthcare staff in order to reduce the social stigma within the school environment. RESULTS: The intervention was effective in reducing the CAMI authoritarianism and social restrictiveness subscales. The intervention showed significant changes in girls in terms of authoritarianism and social restrictiveness, while boys only showed significant changes in authoritarianism. Following the intervention, a significant reduction was found in authoritarianism and social restrictiveness in those who knew someone with mental illness, and only in authoritarianism in those who did not know anyone with mental illness. CONCLUSION: The intervention was effective to reduce social stigma towards people with mental illness, especially in the area of authoritarianism. Some differences were found depending on gender and whether or not the subjects knew someone with mental illness. | Regina Vila-Badia Francisco Martínez-Zambrano Otilia Arenas Emma Casas-Anguera Esther García-Morales Raúl Villellas José Ramón Martín María Belén Pérez-Franco Tamara Valduciel Diana Casellas Mar García-Franco Jose Miguel Joaquim Balsera Gemma Pascual Eugènia Julia Susana Ochoa | 2016 | World Journal of Psychiatry2016，6，2： | 4 |
| 2 | The mystery of phantom pain:growing evidence for psychophysiological mechanisms 显示文摘 | Sherman RA Arena JG Sherman CJ | 1989 | Biofeedback SelfRegul1989，14，4： | 1 |
| 3 | Phantom limb pain:mechanisms,incidence,and treatment 显示文摘 | Sherman RA Arena JG | 1992 | Crit Rev Phys Rehad Med1992，4，12： | 1 |
| 4 | Phantom limb pain:mechanisms,incidence,and treatment显示文摘 | Arena JG | 1992 | Crit Rev Phys Rehad Med1992，4，： | 1 |
| 5 | Enhanced interleu- kin- 1 activity contributes to exercise intolerance in patients with systolic heart failure显示文摘 | Van Tassell BW Arena RA Stefano T | 2012 | PLoS One2012，7，33： | 1 |
| 6 | Enhanced interleu- kin - 1 activity contributes to exercise intolerance in patients with systolic heart failure显示文摘 | Vant Tassell BW Arena RA Stefano T | 2012 | PLoS One2012，7，33： | 1 |
| 7 | The utility of cardiopulmonary exercise testing to detect and track early-stage ischemic heart disease显示文摘 | Chaudhry S Arena RA Hansen JE | 2010 | Mayo Clin Proc2010，85，： | 1 |
| 8 | Breathing exercises and inspiratory muscle training in heart failure 显示文摘 | Cahalin LP Arena RA | 2015 | Heart Fail Clin2015，11，1： | 1 |
| 9 | Phantom limb pain : mechanisms, incidence, and treatment 显示文摘 | Sherman RA Arena JG | 1992 | Crit Rev Phys ehadMed1992，4，： | 1 |
| 10 | Serum levels of inter- leukin - 10 in patients affected by breast cancer 显示文摘 | Merendino RA Arena A Capozza AB | 1996 | Immunol Lett1996，53，： | 1 |
| 11 | Phantom limb pain: mechanisms, inci- dence,and treatment 显示文摘 | Sherman RA Arena JG | 1992 | Crit Rev Phys Rehad Med1992，4，12： | 1 |
| 12 | The utility of cardiopulmonary exereise testing to detect aod track early -stage ischemic heart disease 显示文摘 | Chaudhry S Arena RA Hansen JE | 2010 | Mayo Clin Proc2010，85，10： | 1 |
| 13 | Phantom limb paint mechanisms, incidence, and treatment显示文摘 | Sherman RA Arena JG | 1992 | Crit Rev Phys Rehad Med1992，4，： | 1 |
| 14 | Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar(CT-P13)in patients with inflammatory bowel disease显示文摘BACKGROUND Infliximab original has changed the natural history of inflammatory bowel diseases(IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the first Infliximab biosimilar into the European and Spanish markets. Currently switching drugs data in IBD are limited. AIM To compare the efficacy of infliximab biosimilar, CT-P13, against infliximab original, analyzing the loss of response of both at the 12 mo follow-up in patients with IBD.METHODS An observational study of two cohorts has been conducted. One retrospective cohort that included patients with IBD treated with Infliximab original, and a prospective cohort of patients who were switching from infliximab original to infliximab biosimilar(CT-P13). We had analyzed the overall efficacy and loss of efficacy in patients in remission at the end of one year after treatment with the original drug compared to the results of the year of treatment with the biosimilar.RESULTS98 patients(CD 67, CU 31) were included in both cohorts. The overall efficacy for infliximab original per year of treatment was 71% vs 68.2% for infliximab biosimilar(P = 0.80). The loss of overall efficacy at 12 mo for infliximab original was 6.6% vs 14.5% for infliximab biosimilar(P = 0.806). The loss of efficacy in patients who were in basal remission was 16.3% for infliximab original vs 27.1% for infliximab biosimilar. Adverse events were 9.2% for infliximab original vs 11.2% for infliximab biosimilar. CONCLUSION The overall efficacy and loss of treatment response with infliximab biosimilar(CT-P13) is similar to that observed with infliximab original in patients who were switching at the 12 mo follow-up. There is no difference in the rate of adverse events. | María Fernanda Guerra Veloz Federico Argüelles-Arias Luisa Castro Laria Belén Maldonado Pérez Antonio Benítez Roldan Raúl Perea Amarillo Vicente Merino Bohórquez Miguel Angel Calleja Angel Caunedo Alvarez Angel Vilches Arenas | 2018 | World Journal of Gastroenterology2018，24，46： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员